ATE369845T1 - Behandlung der nebenwirkungen von statinen - Google Patents
Behandlung der nebenwirkungen von statinenInfo
- Publication number
- ATE369845T1 ATE369845T1 AT01998341T AT01998341T ATE369845T1 AT E369845 T1 ATE369845 T1 AT E369845T1 AT 01998341 T AT01998341 T AT 01998341T AT 01998341 T AT01998341 T AT 01998341T AT E369845 T1 ATE369845 T1 AT E369845T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- relates
- side effects
- uridine
- therapy
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 abstract 6
- 238000002560 therapeutic procedure Methods 0.000 abstract 4
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 abstract 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 abstract 3
- 235000017471 coenzyme Q10 Nutrition 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 abstract 3
- 229940045145 uridine Drugs 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 Coenzyme Q10 (Q10) Chemical compound 0.000 abstract 1
- 206010049565 Muscle fatigue Diseases 0.000 abstract 1
- 208000000112 Myalgia Diseases 0.000 abstract 1
- 150000004054 benzoquinones Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 abstract 1
- 229940110767 coenzyme Q10 Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000013465 muscle pain Diseases 0.000 abstract 1
- SOECUQMRSRVZQQ-UHFFFAOYSA-N ubiquinone-1 Chemical compound COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O SOECUQMRSRVZQQ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dental Preparations (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR1773A AUPR177300A0 (en) | 2000-11-29 | 2000-11-29 | Therapeutic methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE369845T1 true ATE369845T1 (de) | 2007-09-15 |
Family
ID=3825810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01998341T ATE369845T1 (de) | 2000-11-29 | 2001-11-29 | Behandlung der nebenwirkungen von statinen |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20040063661A1 (https=) |
| EP (1) | EP1343488B1 (https=) |
| JP (2) | JP4596734B2 (https=) |
| AT (1) | ATE369845T1 (https=) |
| AU (3) | AUPR177300A0 (https=) |
| CA (1) | CA2429979C (https=) |
| DE (1) | DE60130023T2 (https=) |
| ES (1) | ES2292643T3 (https=) |
| NZ (1) | NZ526069A (https=) |
| WO (1) | WO2002043721A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR951101A0 (en) | 2001-12-13 | 2002-01-24 | Centre For Molecular Biology And Medicine | Method of treatment |
| WO2004105742A1 (en) * | 2003-06-02 | 2004-12-09 | Isis Innovation Limited | Treatment of muscle fatigue |
| EP1648952B1 (en) | 2003-06-03 | 2018-03-07 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
| ES2809302T3 (es) | 2004-01-22 | 2021-03-03 | Univ Miami | Formulaciones de coenzima Q10 para tratar tumores sólidos mediante administración intravenosa |
| US20050288379A1 (en) * | 2004-06-21 | 2005-12-29 | Xiaoqiang Yan | Benzoquinone compounds as anti-cancer agents |
| JP2008503579A (ja) * | 2004-06-21 | 2008-02-07 | ハッチソン メディファーマ エンタープライジズ リミテッド | 癌の化学療法 |
| WO2006057209A1 (ja) * | 2004-11-26 | 2006-06-01 | Sankyo Company, Limited | 血中遊離脂肪酸低下作用を有する医薬組成物 |
| JP4896501B2 (ja) * | 2004-11-26 | 2012-03-14 | 第一三共株式会社 | 血中遊離脂肪酸低下作用を有する医薬組成物 |
| US20060252830A1 (en) * | 2005-05-06 | 2006-11-09 | Brandon Stephen F | Method for the treatment of magnesium and potassium deficiencies |
| US20060252831A1 (en) * | 2005-05-06 | 2006-11-09 | Christopher Offen | Method for the treatment of magnesium and potassium deficiencies |
| EP2471530B1 (en) | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EP3369738B1 (en) * | 2005-11-18 | 2020-05-20 | Cornell Research Foundation, Inc. | Method for making nicotinoyl ribosides and nicotinamide beta-riboside |
| JP2009527504A (ja) * | 2006-02-23 | 2009-07-30 | イオメディックス スリープ インターナショナル エスアールエル | 良質な睡眠の誘導および維持のための組成物および方法 |
| WO2007127908A2 (en) * | 2006-04-28 | 2007-11-08 | Hutchison Medipharma Enterprises Limited | Dihydrobenzoquinone compounds |
| CA2977089A1 (en) * | 2006-05-02 | 2007-11-15 | University Of Miami | Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds |
| EP2240017B1 (en) | 2008-01-04 | 2019-03-13 | Oxford University Innovation Limited | Ketone bodies and ketone body esters as blood lipid lowering agents |
| PE20091564A1 (es) | 2008-02-29 | 2009-11-04 | Biolab Sanus Farmaceutica Ltda | Composicion farmaceutica de un derivado racetam y carnitina |
| AU2009233785B2 (en) | 2008-04-11 | 2015-08-20 | Berg Llc | Methods and use of inducing apoptosis in cancer cells |
| US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| JP5426918B2 (ja) * | 2009-04-20 | 2014-02-26 | 株式会社 伊藤園 | ウリジンを含有する抗疲労剤又は体力向上剤 |
| AU2010247800A1 (en) | 2009-05-11 | 2011-12-15 | Berg Llc | Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| US8557236B2 (en) * | 2010-02-09 | 2013-10-15 | Vascure Natural LLC | Cardiovascular support supplement and compositions and methods thereof |
| GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
| CA2832324C (en) | 2011-04-04 | 2022-03-15 | Berg Llc | Methods of treating central nervous system tumors |
| US9642860B2 (en) | 2011-08-15 | 2017-05-09 | Technion Research & Development Foundation Limited | Combinations of corroles and statins |
| TWI504390B (zh) * | 2012-09-18 | 2015-10-21 | Univ China Medical | 苯醌類化合物應用於抑制黑色素瘤細胞之Ｗｎｔ／β－ｃａｔｅｎｉｎ訊息途徑之用途 |
| TWI489982B (zh) * | 2012-09-18 | 2015-07-01 | Univ China Medical | 苯醌類化合物應用於抑制動脈粥狀血管硬化之用途 |
| DK2914251T3 (da) | 2012-11-05 | 2019-11-04 | Us Health | Ketonlegemer til beskyttelse af væv mod beskadigelse som følge af ioniseringsstråling |
| GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
| GB2515603B (en) | 2013-03-14 | 2015-10-14 | Isis Innovation | Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate |
| SG10201903112WA (en) | 2013-04-08 | 2019-05-30 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
| WO2015003246A1 (en) * | 2013-07-09 | 2015-01-15 | Mcmaster University | Combination of a statin with an inflammasome inhibitor |
| KR102370843B1 (ko) | 2013-09-04 | 2022-03-04 | 버그 엘엘씨 | 코엔자임 q10의 연속주입에 의한 암치료 방법 |
| WO2017087576A1 (en) | 2015-11-16 | 2017-05-26 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| DK3634391T3 (da) | 2017-05-17 | 2025-03-31 | Bpgbio Inc | Anvendelse af coenzym q10-formuleringer i behandlingen og forebyggelsen af epidermolysis bullosa |
| WO2018218287A1 (en) * | 2017-05-29 | 2018-12-06 | Woodlinda Pty Ltd | Treatment and/or prevention of neuropathic symptoms associated with diabetes mellitus type ii |
| CA3078808A1 (en) * | 2017-10-13 | 2018-10-12 | Exerkine Corporation | Use of system xc- inhibitor for treating statin-induced myalgia |
| KR102060722B1 (ko) * | 2017-11-06 | 2020-02-11 | 연세대학교 산학협력단 | 스타틴에 의한 약물유해반응용 동물 모델 및 이의 제조방법 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2462312A1 (de) * | 1974-03-04 | 1976-10-14 | Nadrol Chemie Pharma Keizer Kg | Arzneimittel zur behandlung von migraene-erkrankungen |
| SU988814A1 (ru) * | 1979-11-20 | 1983-01-15 | Филиал Всесоюзного научно-исследовательского химико-фармацевтического института им.Серго Орджоникидзе | Соли оротовой кислоты и @ -аминокислот, предупреждающие развитие утомлени при физических нагрузках |
| DE3110560A1 (de) * | 1981-03-18 | 1982-10-14 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben" |
| US4911917A (en) * | 1988-06-28 | 1990-03-27 | Hauser-Kuhrts, Inc. | Cholesterol-lowering combination comopsitions of magnesium salt and niacin |
| CA2007983C (en) * | 1989-01-18 | 1996-12-10 | Michael S. Brown | Coenzyme q10 with hmg-coa reductase inhibitors |
| US4929437A (en) * | 1989-02-02 | 1990-05-29 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
| US5316765A (en) * | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
| JPH07504198A (ja) * | 1992-02-24 | 1995-05-11 | イースト カロライナ ユニバーシティ | デヒドロエピアンドロステロンおよびその類縁体を用いる処置によって発癌を抑制する方法 |
| BE1005939A6 (fr) * | 1992-05-14 | 1994-03-15 | Pirmez Thierry Dr | Utilisation des sels de l'acide orotique comme tranporteurs preferentiels d'oligo-elements. |
| ATE271614T1 (de) * | 1992-05-28 | 2004-08-15 | Ct For Molecular Biology And M | Quinone-derivate zur verbesserung der zellulare bioenergie |
| AT405477B (de) * | 1996-04-03 | 1999-08-25 | Norbert Mag Fuchs | Kombinationspräparat |
| US6472378B2 (en) * | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
| US6245800B1 (en) * | 1999-06-08 | 2001-06-12 | Sigma-Tau | Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine |
| IT1317008B1 (it) * | 2000-04-04 | 2003-05-26 | Sigma Tau Healthscience Spa | Integratore alimentare energizzante sulla muscolatura scheletrica eprotettivo sull'apparato cardiovascolare. |
| US6420342B1 (en) * | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
-
2000
- 2000-11-29 AU AUPR1773A patent/AUPR177300A0/en not_active Abandoned
-
2001
- 2001-11-29 WO PCT/AU2001/001545 patent/WO2002043721A1/en not_active Ceased
- 2001-11-29 ES ES01998341T patent/ES2292643T3/es not_active Expired - Lifetime
- 2001-11-29 EP EP01998341A patent/EP1343488B1/en not_active Expired - Lifetime
- 2001-11-29 AU AU2330202A patent/AU2330202A/xx active Pending
- 2001-11-29 JP JP2002545692A patent/JP4596734B2/ja not_active Expired - Fee Related
- 2001-11-29 CA CA2429979A patent/CA2429979C/en not_active Expired - Fee Related
- 2001-11-29 DE DE60130023T patent/DE60130023T2/de not_active Expired - Lifetime
- 2001-11-29 AT AT01998341T patent/ATE369845T1/de not_active IP Right Cessation
- 2001-11-29 AU AU2002223302A patent/AU2002223302B2/en not_active Ceased
- 2001-11-29 NZ NZ526069A patent/NZ526069A/en not_active IP Right Cessation
- 2001-11-29 US US10/433,074 patent/US20040063661A1/en not_active Abandoned
-
2010
- 2010-02-16 US US12/706,257 patent/US20100144665A1/en not_active Abandoned
- 2010-07-02 JP JP2010151665A patent/JP2010248230A/ja active Pending
- 2010-08-04 US US12/849,943 patent/US20100323981A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2292643T3 (es) | 2008-03-16 |
| JP4596734B2 (ja) | 2010-12-15 |
| CA2429979A1 (en) | 2002-06-06 |
| AU2330202A (en) | 2002-06-11 |
| EP1343488B1 (en) | 2007-08-15 |
| EP1343488A1 (en) | 2003-09-17 |
| CA2429979C (en) | 2011-11-15 |
| DE60130023D1 (de) | 2007-09-27 |
| WO2002043721A1 (en) | 2002-06-06 |
| US20100144665A1 (en) | 2010-06-10 |
| HK1059044A1 (en) | 2004-06-18 |
| AU2002223302B2 (en) | 2006-08-31 |
| US20100323981A1 (en) | 2010-12-23 |
| JP2010248230A (ja) | 2010-11-04 |
| NZ526069A (en) | 2006-11-30 |
| DE60130023T2 (de) | 2008-05-08 |
| AUPR177300A0 (en) | 2000-12-21 |
| US20040063661A1 (en) | 2004-04-01 |
| EP1343488A4 (en) | 2005-05-04 |
| JP2004531468A (ja) | 2004-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE369845T1 (de) | Behandlung der nebenwirkungen von statinen | |
| CY1111951T1 (el) | Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου | |
| CY1109242T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου | |
| SG151286A1 (en) | 5-substituted-2-phenylamino-benzamide as mek inhibitor | |
| BR0309343A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
| DE69229442D1 (de) | Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| TW200639159A (en) | Treatment of pain | |
| DE69629282D1 (de) | Verwendung eines pyruvatdehydrogenaseaktivators zur behandlung der ischämie in gliedern | |
| ATE472323T1 (de) | Behandlung von statin-nebenwirkungen mit uridinderivaten | |
| SG146685A1 (en) | Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them | |
| NZ503027A (en) | Use of rifamycin derivative for treating mastitis in a domestic animal | |
| EP1325918A4 (en) | INHIBITORS OF CARDIAC MUSCLE CELL APOPTOSIS AND THERAPEUTIC / PROPHYLACTIC AGENTS AGAINST HEART DISEASE | |
| TW200730177A (en) | 4 anilino-3-quinolinecarbonitriles for the treatment of cancer | |
| EA200600271A1 (ru) | Применение производных индазола для лечения невропатической боли | |
| DE60108775T8 (de) | Methode zur behandlung von schlaganfall | |
| DK1011672T3 (da) | Anvendelse af (E)-metanicotin derivater til frembringelse af analgetiske virkninger | |
| WO2003090737A3 (en) | Methods and compositions for treatment of cancer pain | |
| DE60034580D1 (de) | Peptid zur behandlung von nervenerkrankungen | |
| TW200420293A (en) | Pharmaceutical compositions for the reduction of gastric acid concentration in blood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |